# aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
Canonical URL: https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-topline-results-from-phase-3-efzo-fittm-study-of-efzofitimod-in-pulmonary-sarcoidosis
Ticker: ATYR
Company: aTyr Pharma
Source: aTyr Pharma
Published: 2025-09-15 11:30 EST
Original Source URL: https://investors.atyrpharma.com
## Summary

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week

## Article Body
Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week
## Recent Company News
- 2026-05-15 12:00 EST — [aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-first-quarter-2026-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-05-13 20:01 EST — [aTyr Pharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ATYR/atyr-pharma-to-participate-in-upcoming-investor-conferences) — Source: aTyr Pharma
- 2026-05-11 20:01 EST — [aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting](https://biopharmsignal.com/news/ATYR/atyr-pharma-provides-regulatory-and-clinical-update-for-efzofitimod-in-pulmonary-sarcoidosis-following-fda-type-c-meeting) — Source: aTyr Pharma
- 2026-03-05 21:01 EST — [aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-02-20 21:01 EST — [aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: aTyr Pharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)